Aspen Neuroscience is at the forefront of developing personalized cell therapies, particularly focusing on Parkinson's disease. The company utilizes a proprietary platform that combines stem cell biology and genomics to create autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapies. Their flagship product, ANPD001, is currently undergoing clinical trials and has received both Investigational New Drug (IND) clearance and Fast Track designation from the FDA. This innovative approach involves reprogramming a patient's own skin cells into iPSCs, which are then differentiated into dopaminergic neuronal precursor cells (DANPCs) for therapeutic use. The manufacturing process is closely monitored through a genomics platform that employs machine learning to ensure cell quality at every stage.

In collaboration with Cell X Technologies, Aspen Neuroscience is advancing its automated manufacturing capabilities to enhance the scalability and efficiency of its personalized cell therapy programs. This partnership aims to streamline the iPSC production process, making it less labor-intensive and more consistent. The Celligent™ platform, which integrates robotics and artificial intelligence, will play a crucial role in achieving these goals. By automating the generation of iPSCs and improving the overall manufacturing workflow, Aspen Neuroscience is positioning itself to meet the growing demand for personalized therapies, ultimately aiming to address the significant unmet medical needs of patients with Parkinson's disease and other neurological conditions.

United States

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Aspen Neuroscience

Company Details